Chemo-Induced Peripheral Neuropathy

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Chemotherapy-induced peripheral neuropathy (CIPN) is a common treatment-related adverse effect and affects long-term quality of life.1 It has the potential to result in chemotherapy dose reductions and/or early discontinuation.The purpose of this study is to provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult …

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Read More »

Rodent Models of Chemotherapy-Induced Peripheral Neuropathy

A common complication of chemotherapy is neurotoxicity that often manifests itself as peripheral neuropathy. Many cancer drugs can cause chemotherapy-induced peripheral neuropathy (CIPN), and the incidence can be up to 90%. A significant percentage of patients improve once the offending drug is stopped, but as much as 50% of the affected individuals are left with …

Rodent Models of Chemotherapy-Induced Peripheral Neuropathy Read More »

Ethoxyquin Prevents Chemotherapy-Induced Neurotoxicity via Hsp90 Modulation

A team of researchers has just published their results of a study to determine if there was a way to prevent peripheral neuropathy from pacitaxel, a chemo-therapy drug used to treat solid tumors. Their research may offer a new opportunity for the development of drugs to prevent paclitaxel-induced PN without blocking paclitaxel’s ability to kill …

Ethoxyquin Prevents Chemotherapy-Induced Neurotoxicity via Hsp90 Modulation Read More »

Nutraceuticals and Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Systematic Review

A team of researchers at Queensland, School of Medicine, reviewed 24 studies to determine if nutraceuticals (i.e., vitamin E, acetyl-L-carnitine, glutamine, glutathione, alpha lipoic acid, magnesium, and others) are effective in reducing the peripheral neuropathy side effect in patients who have received chemotherapy treatments. The studies were mixed and currently no agent has shown solid …

Nutraceuticals and Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Systematic Review Read More »

Duloxetine May Ease Neuropathy from Chemo

Ellen Lavoie Smith, PhD, University of Michigan School of Nursing, and her team have published results of a phase 3 study showing that patients receiving duloxetine had a reduction in pain symptoms over a 5 week period. And, more patients initially treated with duloxetine, had even greater incidence of pain reduction.  READ MORE from MedPage Today …

Duloxetine May Ease Neuropathy from Chemo Read More »

Mayo Researchers Identify Gene Variations that Predict Chemotherapy Side Effects

Small differences in genetic code from one person to the next could influence who develops side effects to chemotherapy. Andreas Butler, MD, oncologist at Mayo Clinic and senior author of the study, reported that three genes (EPHA5, ARHGEF10, and PRX) were the focus of their study and are the first to mine large swaths of …

Mayo Researchers Identify Gene Variations that Predict Chemotherapy Side Effects Read More »

MLN9708 Regimen Effective with Reduced Neuropathy Risk in Multiple Myeloma

At the American Society of Hematology annual meeting, Dr. Shaji Kumar presented the results of a recent Phase I/II study conducted at the Mayo Clinic. Newly diagnosed multiple myeloma patients were given an oral regimen containing an experimental preteasome inhibitor – MLN9708. With promising results, more evaluation is being done on relapsed and newly diagnosed myeloma.  …

MLN9708 Regimen Effective with Reduced Neuropathy Risk in Multiple Myeloma Read More »

DARA BioSciences Announces Submission of KRN5500 to FDA for Orphan Drug Status

In October 2011, the FDA designated KRN5500 – a drug being developed to treat chronic chemotherapy-induced PN (CCIPN) – with ‘Fast Track’ status. Today DARA BioSciences applied for orphan drug status for KRN5500. Orphan drug status is provided to products that treat rare conditions for which there are few adequate therapies. No approved treatments currently …

DARA BioSciences Announces Submission of KRN5500 to FDA for Orphan Drug Status Read More »

Acetyl-l-Carnitine Yield Mixed Results for Chemo-Induced Neuropathy

Two clinical trials, one in the US and one in China have been completed on the results of taking Acetyl-l-Carnitine, either during chemotherapy treatments or before treatment. With very different results presented at the American Society of Clinical Oncology annual meeting, there is no clear direction on the use of ALC. Debra Barton, PhD, Mayo Clinic, commented, “Further …

Acetyl-l-Carnitine Yield Mixed Results for Chemo-Induced Neuropathy Read More »

Omega-3 Fatty Acids are Protective Against Paclitaxel-induced Peripheral Neuropathy

First published online by BioMed Central, researchers from Tehran and Tabriz Universities, Iran, have found that Omega-3 fatty acids have beneficial effects on neurological disorders from the side effects of paclitaxel, used to treat breast cancer. Omega-3 fatty acids may be an efficient neuroprotective agent against paclitaxel-induced PN.  READ MORE Source: Equities.com